These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12606608)

  • 1. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy.
    Kapur S; VanderSpek SC; Brownlee BA; Nobrega JN
    J Pharmacol Exp Ther; 2003 May; 305(2):625-31. PubMed ID: 12606608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery.
    Samaha AN; Reckless GE; Seeman P; Diwan M; Nobrega JN; Kapur S
    Biol Psychiatry; 2008 Jul; 64(2):145-52. PubMed ID: 18295747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
    Turrone P; Remington G; Kapur S; Nobrega JN
    Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
    Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
    Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients.
    Catafau AM; Penengo MM; Nucci G; Bullich S; Corripio I; Parellada E; García-Ribera C; Gomeni R; Merlo-Pich E;
    J Psychopharmacol; 2008 Nov; 22(8):882-94. PubMed ID: 18308793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer.
    Barth VN; Chernet E; Martin LJ; Need AB; Rash KS; Morin M; Phebus LA
    Life Sci; 2006 May; 78(26):3007-12. PubMed ID: 16434058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects.
    Wadenberg ML; Soliman A; VanderSpek SC; Kapur S
    Neuropsychopharmacology; 2001 Nov; 25(5):633-41. PubMed ID: 11682246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
    Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine-antipsychotic drug interactions and attentional performance in female rats.
    Rezvani AH; Levin ED
    Eur J Pharmacol; 2004 Feb; 486(2):175-82. PubMed ID: 14975706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.
    Perez-Costas E; Guidetti P; Melendez-Ferro M; Kelley JJ; Roberts RC
    J Neural Transm (Vienna); 2008 May; 115(5):745-53. PubMed ID: 18193153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats.
    Turrone P; Remington G; Kapur S; Nobrega JN
    Neuropsychopharmacology; 2003 Aug; 28(8):1433-9. PubMed ID: 12838271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
    Yamada Y; Ohno Y; Nakashima Y; Fukuda M; Takayanagi R; Sato H; Tsuchiya F; Sawada Y; Iga T
    Synapse; 2002 Oct; 46(1):32-7. PubMed ID: 12211096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing.
    Nemeroff CB; Kinkead B; Goldstein J
    J Clin Psychiatry; 2002; 63 Suppl 13():5-11. PubMed ID: 12562141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench.
    Kapur S; Wadenberg ML; Remington G
    Can J Psychiatry; 2000 Apr; 45(3):241-6. PubMed ID: 10779880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.